RxDoctor Payments Data

Jorge Valdesuso, MD

General Practice · San Juan, PRNPI 1801830427

Payments from drug & device makers

$1,401in general payments, 2019–2025

Across 33 payments — averaging $42.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$608
  • Lilly USA, LLC$231
  • Biocryst US Sales Co., LLC$192
  • AstraZeneca$144
  • Boehringer Ingelheim$121
  • PBG Puerto Rico LLC$40
  • plus $65 from 3 others

What the payments were for

  • Food & beverage$1,401100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson12$608
Lilly USA, LLC2$231
Biocryst US Sales Co., LLC11$192
AstraZeneca2$144
Boehringer Ingelheim1$121
PBG Puerto Rico LLC2$40
Exact Sciences1$25
Amgen1$20
AbbVie1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,401 in reported general payments places this provider in the 90th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$8,808
Medicare patients
34
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin51$69,476
EliquisApixaban46$52,483
SynthroidLevothyroxine Sodium412$48,457
MounjaroTirzepatide41$46,078
OzempicSemaglutide38$39,145
FarxigaDapagliflozin Propanediol33$30,611
Trijardy XrEmpaglifloz/Linaglip/Metformin26$29,572
JanumetSitagliptin Phos/Metformin Hcl34$25,527
XareltoRivaroxaban17$24,262
JanuviaSitagliptin Phosphate18$24,245
TradjentaLinagliptin16$20,728
Diclofenac Potassium416$16,559
TrulicityDulaglutide16$15,800
LantusInsulin Glargine,hum.Rec.Anlog100$11,350
Gabapentin557$10,806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Trijardy Xr, Tradjenta, Synjardy Xr, Stiolto Respimat$121$133,152116 claims
Lilly USA, LLCMounjaro, Trulicity, Cymbalta, Humulin N, Humalog Mix 75-25$231$76,482131 claims
AbbVieSynthroid, Lumigan$20$57,827445 claims
AstraZenecaFarxiga$144$30,61133 claims
Johnson & JohnsonXarelto$608$24,26217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →